Cargando…

Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient

INTRODUCTION: Coronavirus disease-2019 (COVID) in patients with advanced heart failure presents unprecedented challenges in management of cardiogenic shock. Recommendations for perioperative triaging of cardiac surgery have been proposed but none regarding LVAD implantation. To our knowledge, we are...

Descripción completa

Detalles Bibliográficos
Autores principales: Dib, E.P., Joseph, S., Patel, N., Rafael, A., Meyer, D., Bindra, A., Hall, S., Gong, T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979386/
http://dx.doi.org/10.1016/j.healun.2021.01.1300
_version_ 1783667273361260544
author Dib, E.P.
Joseph, S.
Patel, N.
Rafael, A.
Meyer, D.
Bindra, A.
Hall, S.
Gong, T.
author_facet Dib, E.P.
Joseph, S.
Patel, N.
Rafael, A.
Meyer, D.
Bindra, A.
Hall, S.
Gong, T.
author_sort Dib, E.P.
collection PubMed
description INTRODUCTION: Coronavirus disease-2019 (COVID) in patients with advanced heart failure presents unprecedented challenges in management of cardiogenic shock. Recommendations for perioperative triaging of cardiac surgery have been proposed but none regarding LVAD implantation. To our knowledge, we are the first to report on LVAD implantation in a patient with COVID and cardiogenic shock CASE REPORT: A 37-year-old-male with Stage D, NYHA class IV heart failure on chronic milrinone was admitted for cardiogenic shock. Despite uptitration of milrinone and addition of dobutamine,the patient remained in cardiogenic shock . Our Selection Committee discussed and approved him for an LVAD. Institutional protocol required COVID screening prior to surgery and returned positive. Given the absence of clinical signs of COVID infection contrasted with the severity of shock, the decision was made to proceed with implantation. Temporary mechanical support was considered but not thought to mitigate risks of thrombosis rather adding procedural risk with ECMO cannulation and left ventricular unloading. He successfully underwent LVAD implantation as INTERMACS 1. He required high doses of heparin to achieve ACT for cardiopulmonary bypass. On day 2, he developed left-sided weakness with imaging revealing multifocal acute cerebral infarcts. Despite normal LVAD function, the embolic infarcts to multiple organs led to further deterioration and death SUMMARY: LVAD implantation in COVID patients appears inevitable. Centers must risk stratify this cohort to reduce susceptibility to thrombosis and improve outcomes. We propose an algorithm that triages patients for elective and urgent LVAD implantation based on specific coagulation and inflammatory markers (figure 1) and have successfully implanted an LVAD in a COVID patient using this. We acknowledge this method has not been validated in a large cohort and are unable to recommend anticoagulation protocols. Further research is necessary to address safety of LVAD implantation in COVID patients
format Online
Article
Text
id pubmed-7979386
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-79793862021-03-23 Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient Dib, E.P. Joseph, S. Patel, N. Rafael, A. Meyer, D. Bindra, A. Hall, S. Gong, T. J Heart Lung Transplant 1183 INTRODUCTION: Coronavirus disease-2019 (COVID) in patients with advanced heart failure presents unprecedented challenges in management of cardiogenic shock. Recommendations for perioperative triaging of cardiac surgery have been proposed but none regarding LVAD implantation. To our knowledge, we are the first to report on LVAD implantation in a patient with COVID and cardiogenic shock CASE REPORT: A 37-year-old-male with Stage D, NYHA class IV heart failure on chronic milrinone was admitted for cardiogenic shock. Despite uptitration of milrinone and addition of dobutamine,the patient remained in cardiogenic shock . Our Selection Committee discussed and approved him for an LVAD. Institutional protocol required COVID screening prior to surgery and returned positive. Given the absence of clinical signs of COVID infection contrasted with the severity of shock, the decision was made to proceed with implantation. Temporary mechanical support was considered but not thought to mitigate risks of thrombosis rather adding procedural risk with ECMO cannulation and left ventricular unloading. He successfully underwent LVAD implantation as INTERMACS 1. He required high doses of heparin to achieve ACT for cardiopulmonary bypass. On day 2, he developed left-sided weakness with imaging revealing multifocal acute cerebral infarcts. Despite normal LVAD function, the embolic infarcts to multiple organs led to further deterioration and death SUMMARY: LVAD implantation in COVID patients appears inevitable. Centers must risk stratify this cohort to reduce susceptibility to thrombosis and improve outcomes. We propose an algorithm that triages patients for elective and urgent LVAD implantation based on specific coagulation and inflammatory markers (figure 1) and have successfully implanted an LVAD in a COVID patient using this. We acknowledge this method has not been validated in a large cohort and are unable to recommend anticoagulation protocols. Further research is necessary to address safety of LVAD implantation in COVID patients Published by Elsevier Inc. 2021-04 2021-03-20 /pmc/articles/PMC7979386/ http://dx.doi.org/10.1016/j.healun.2021.01.1300 Text en Copyright © 2021 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle 1183
Dib, E.P.
Joseph, S.
Patel, N.
Rafael, A.
Meyer, D.
Bindra, A.
Hall, S.
Gong, T.
Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient
title Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient
title_full Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient
title_fullStr Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient
title_full_unstemmed Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient
title_short Left Ventricular Assist Device Implantation in a COVID-19 Positive Patient
title_sort left ventricular assist device implantation in a covid-19 positive patient
topic 1183
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7979386/
http://dx.doi.org/10.1016/j.healun.2021.01.1300
work_keys_str_mv AT dibep leftventricularassistdeviceimplantationinacovid19positivepatient
AT josephs leftventricularassistdeviceimplantationinacovid19positivepatient
AT pateln leftventricularassistdeviceimplantationinacovid19positivepatient
AT rafaela leftventricularassistdeviceimplantationinacovid19positivepatient
AT meyerd leftventricularassistdeviceimplantationinacovid19positivepatient
AT bindraa leftventricularassistdeviceimplantationinacovid19positivepatient
AT halls leftventricularassistdeviceimplantationinacovid19positivepatient
AT gongt leftventricularassistdeviceimplantationinacovid19positivepatient